NICE prepared to recommend Soliris for treatment of Hemolytic Uremic Syndrome- Alexion
In new draft guidance, the National Institute for Health and Care Excellence (NICE) proposes to recommend the use of Soliris (eculizumab) from Alexion Pharma in the treatment of atypical Haemolytic Uraemic Syndrome (aHUS), an extremely rare but life-threatening disease which causes inflammation of blood vessels and the formation of blood clots throughout the body.
There are approximately 200 people in England who are affected by aHUS and are at constant risk of sudden and progressive damage to and failure of their vital organs, especially the kidneys.
Soliris is approved in the EU and USA for treatment of Hemolytic Uremic Syndrome (aHUS).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.